GLP‑1 weight‑loss drugs linked to better job and relationship outcomes for women and reduced binge‑eating symptoms

A Harvard economics study found that women who began GLP‑1 weight‑loss medication and lost weight experienced notable socioeconomic gains. After about 18 months, single women reported a 29% rise in marriage or cohabitation, and women who were unemployed saw a 27% increase in job prospects, while employed women showed no clear career advancement.

A separate systematic review and meta‑analysis by University College London examined 25 randomized trials involving 8,069 participants across 12 countries. The analysis showed that GLP‑1 receptor agonists—semaglutide, tirzepatide and liraglutide—were associated with fewer binge‑eating episodes, reduced emotional eating, less loss‑of‑control around food, and greater dietary restraint. Researchers note these effects appear to go beyond weight loss, potentially involving brain pathways that regulate hunger, reward and impulse control, but stress that most evidence is short‑term and longer‑term studies are needed.